Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

42P - Genetic polymorphism of lncRNA PCAT1 and gastric cancer risk

Date

17 Sep 2020

Session

E-Poster Display

Topics

Basic Science

Tumour Site

Presenters

Eun Heui Jin

Citation

Annals of Oncology (2020) 31 (suppl_4): S245-S259. 10.1016/annonc/annonc265

Authors

E.H. Jin

Author affiliations

  • Research Institute For Medical Sciences, Chungnam National University College O, Research Institute for Medical Sciences, Chungnam National University College of Medicine, 35015 - Daejeon/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 42P

Background

Gastric cancer (GC) is one of the most common cancers in the world. The aims of this study were to evaluate the association between a polymorphism rs710886 in long noncoding RNA (lncRNA) prostate cancer-associated transcript 1 (PCAT1) and the risk of GC and GC subgroups via a case-control study.

Methods

Genotyping of rs710886 was conducted by using TaqMan genotyping assay with 460 GC patients and 377 controls.

Results

After adjusted for age and gender, the rs710886 was associated with an increased risk of GC in subjects aged ≥60 years (dominant model: adjusted OR = 1.68, 95% CI = 1.04-2.72, P = 0.035), GC in male subjects (AG: adjusted OR = 2.28, 95% CI = 1.38-3.79, P = 0.001; dominant model: adjusted OR = 1.87, 95% CI = 1.18-2.96, P = 0.008), GC in subjects with well differentiated tumor type (AG: adjusted OR = 1.64, 95% CI = 1.03-2.60, P = 0.037; dominant model: adjusted OR = 1.57, 95% CI = 1.01-2.44, P = 0.046).

Conclusions

Our findings suggest that the rs710886 in lncRNA PCAT1 associated with increased the susceptibility of GC and may exacerbates the development of GC. Further studies are needed to validate our results in large populations as well as different ethnic groups.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

National Research Foundation of Korea.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.